UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling

Nature communications, 2021-03, Vol.12 (1), p.1858-1858, Article 1858

2021

Volltextzugriff (PDF)

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma

PloS one, 2014-04, Vol.9 (4), p.e94281-e94281

2014

Volltextzugriff (PDF)

Reversing the Warburg Effect as a Treatment for Glioblastoma

The Journal of biological chemistry, 2013-03, Vol.288 (13), p.9153-9164

2013

Volltextzugriff (PDF)

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.142-14, Article 142

2019

Volltextzugriff (PDF)

Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells

PloS one, 2012-04, Vol.7 (4), p.e36211-e36211

2012

Volltextzugriff (PDF)

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

Nuclear medicine and biology, 2010-10, Vol.37 (7), p.785-794

2010

Volltextzugriff (PDF)

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

Nature (London), 2015-03, Vol.519 (7543), p.366-369

2015

Volltextzugriff (PDF)

MRP3: a molecular target for human glioblastoma multiforme immunotherapy

BMC cancer, 2010-09, Vol.10 (1), p.468-468, Article 468

2010

Volltextzugriff (PDF)

Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233

Journal of neuro-oncology, 2012-11, Vol.110 (2), p.163-177

2012

Volltextzugriff (PDF)

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma

Clinical cancer research, 2018-08, Vol.24 (15), p.3611-3631

2018

Volltextzugriff (PDF)

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models

Oncotarget, 2016-11, Vol.7 (48), p.79828-79841

2016

Volltextzugriff (PDF)

Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development

Journal of neurochemistry, 2015-06, Vol.133 (5), p.730-738

2015

Volltextzugriff (PDF)

Schedule-dependent Activity of Temozolomide plus CPT-11 against a Human Central Nervous System Tumor-derived Xenograft

Clinical cancer research, 2000-10, Vol.6 (10), p.4154-4157

2000

Volltextzugriff (PDF)

Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab

Nuclear medicine and biology, 2009-08, Vol.36 (6), p.659-669

2009

Volltextzugriff (PDF)

Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors

Nuclear medicine and biology, 2012-01, Vol.39 (1), p.23-34

2012

Volltextzugriff (PDF)

Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis

BMC developmental biology, 2010-11, Vol.10 (1), p.114-114

2010

Volltextzugriff (PDF)

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

Neuro-oncology (Charlottesville, Va.), 2008-04, Vol.10 (2), p.182-189

2008

Volltextzugriff (PDF)

Unarmed, Tumor-Specific Monoclonal Antibody Effectively Treats Brain Tumors

Proceedings of the National Academy of Sciences - PNAS, 2000-06, Vol.97 (13), p.7503-7508

2000

Volltextzugriff (PDF)

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

Journal of clinical oncology, 2000-11, Vol.18 (22), p.3862-3872

2000

Volltextzugriff (PDF)

EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells

Cancer Immunology, Immunotherapy, 2008-01, Vol.57 (1), p.115-121

2008

Volltextzugriff (PDF)

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice

Neuro-oncology (Charlottesville, Va.), 2007-07, Vol.9 (3), p.240-244

2007

Volltextzugriff (PDF)

Regional Treatment of Epidermal Growth Factor Receptor vIII-expressing Neoplastic Meningitis with a Single-Chain Immunotoxin, MR-1

Clinical cancer research, 1999-09, Vol.5 (9), p.2646-2652

1999

Volltextzugriff (PDF)

Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[ 131i]iodo-4-phosphonomethylbenzoate ([ 131i]SIPMB), a negatively charged substituent bearing acylation agent

Nuclear medicine and biology, 2004-10, Vol.31 (7), p.909-919

2004

Volltextzugriff (PDF)

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

Cancer Immunology, Immunotherapy, 2002-02, Vol.50 (12), p.639-652

2002

Volltextzugriff (PDF)

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

Blood, 2004-08, Vol.104 (3), p.642-648

2004

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Research

ThemaTransplantation, Heterologous

ThemaFemale

ThemaMice

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

13 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma

Reversing the Warburg Effect as a Treatment for Glioblastoma

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

MRP3: a molecular target for human glioblastoma multiforme immunotherapy

Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models

Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development

Schedule-dependent Activity of Temozolomide plus CPT-11 against a Human Central Nervous System Tumor-derived Xenograft

Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab

Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors

Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

Unarmed, Tumor-Specific Monoclonal Antibody Effectively Treats Brain Tumors

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice

Regional Treatment of Epidermal Growth Factor Receptor vIII-expressing Neoplastic Meningitis with a Single-Chain Immunotoxin, MR-1

Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[ 131i]iodo-4-phosphonomethylbenzoate ([ 131i]SIPMB), a negatively charged substituent bearing acylation agent

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

Aktive Filter

Suchergebnisse filtern